Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Johnson & Johnson (NY:JNJ)

178.18 -0.58 (-0.32%)
Streaming Delayed Price Updated: 10:14 AM EDT, Sep 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Johnson & Johnson

< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
99 100 Next >
Healthcare And Biotech Stocks Lag The Market Again
Biotech stocks got little help from the JPM Conference despite some recovery to the general market. 
Via Talk Markets
Topics Stocks / Equities
8 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?
These 11 large-cap stocks saw significant growth last week, with notable news from companies such as Johnson & Johnson, MicroStrategy, and United Rentals. 
Via Benzinga
MarketBeat Week in Review – 01/13 - 01/17
The sell-off in stocks reversed abruptly this week on better-than-expected inflation readings; investors will want to see strong earnings to support the rally 
Via MarketBeat
Topics Economy Energy
Looking Into Johnson & Johnson's Recent Short Interest
 
Via Benzinga
2 Beaten-Down Dividend Stocks to Buy in 2025
Via The Motley Fool
3 Super-Safe Dividend Stocks to Buy for 2025 and Beyond
Via The Motley Fool
Wall Street's Greatest Dividend Stock -- a Small-Cap Company 99% of Investors Have Never Heard of -- Is the Cheapest It's Been in Over a Decade
This magnificent company has been paying a continuous dividend to its shareholders since 1816. 
Via The Motley Fool
Deal Dispatch: Biden Punts TikTok Ban To Trump, Plus Another Legacy Retailer Goes Bankrupt
Deal opportunities abound: KKR & Co.'s stake in Maya; DuPont's electronics business; Ingevity's North Charleston site; and S&W Seed Company. 
Via Benzinga
Topics Government
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
Is Johnson & Johnson Stock Set to Reward Long-Term Holders?
JNJ stock is up 1.8% after announcing its $14.6 billion acquisition of Intra-Cellular Therapeutics, which may make this undervalued dividend king attractive 
Via MarketBeat
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever
These companies lead their respective markets, making them must-haves for buy-and-hold dividend investors. 
Via The Motley Fool
10 One Decision Stocks To Buy Now
The following 10 one decision stocks have increased their dividends for over 25 years, making them Dividend Aristocrats. 
Via Talk Markets
Topics Stocks / Equities
Got $200? 2 Dividend Stocks to Buy and Hold Forever
These companies headline a $1.4 trillion industry, have staying power, and will pay you well to hold their stock. 
Via The Motley Fool
What Lies Ahead In 2025? Slower Growth, More Volatility
As we move through 2025, the global economy and financial markets are facing a critical juncture. 
Via Talk Markets
Topics Economy Stocks / Equities
Clinical Research Firm ICON Faces Headwinds From Top Customers And Biotech Recovery Uncertainty
ICON forecasts 2025 revenue at $8.05 billion–$8.65 billion and adjusted EPS of $13.00–$15.00, citing biopharma spending cuts and biotech recovery delays. 
Via Benzinga
Intra-Cellular Therapies Stock Is Surging Monday: What's Going On?
Shares of Intra-Cellular Therapies Inc. (NASDAQ: ITCI) are trading higher Monday after Johnson & Johnson agreed to acquire the company. 
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Enfusion, Inc. (NYSE - ENFN), Intra-Cellular Therapies, Inc. (Nasdaq - ITCI), Paycor HCM, Inc. (Nasdaq - PYCR), Accolade, Inc. (Nasdaq - ACCD)
From Brodsky & Smith LLC
Via GlobeNewswire
Like Bristol-Myers Squibb And AbbVie, Johnson & Johnson Seeks To Bolster Neuropsychiatric Portfolio With $15 Billion Deal
Johnson & Johnson's $14.6 billion acquisition of Intra-Cellular Therapies boosts its CNS portfolio with Caplyta and a promising clinical-stage pipeline. 
Via Benzinga
Johnson & Johnson Buys Intra-Cellular Therapeutics In A Whopping $14.6 Billion Deal
The deal values the smaller biotech company at a 39% premium to last week's closing price. 
Via Investor's Business Daily
Intra-Cellular Therapies Stock Shines Amid Market Slump On J&J’s $14.6B Buyout Deal: Retail Brims With Optimism
ITCI's flagship product, Caplyta, is a once-daily oral therapy approved for treating schizophrenia and depressive episodes linked to bipolar disorders, which reportedly raked in sales of $464 million... 
Via Stocktwits
Johnson & Johnson Strengthens Neuroscience Leadership with Acquisition of Intra-Cellular Therapies, Inc.
From Johnson & Johnson
Via Business Wire
A Look At Dividend Kings
In this video, we dive deep into 'Dividend Kings.' These are elite companies that have consistently increased their dividends for 50+ years. 
Via Talk Markets
Topics ETFs Stocks / Equities
Stock Market Tumbles As Yields Spike; Nvidia, Tesla, Delta, Meta, Jobs Report In Focus: Weekly Review
The S&P 500 and Nasdaq are below their 50-day lines. 
Via Investor's Business Daily
Topics Stocks
4 Top Dividend Growth Stocks to Build Your Portfolio Around in 2025
These companies have track records of success, increasing dividends, and fantastic growth prospects, making them all ideal portfolio anchor stocks for a long-term investor. 
Via The Motley Fool
2 Dow Stocks to Buy Hand Over Fist in 2025 and 1 to Avoid
Among the Dow Jones Industrial Average's 30 components, there are two historically cheap brand-name companies, as well as a new member that's priced for perfection in an imperfect industry. 
Via The Motley Fool
Topics Stocks
Johnson & Johnson Pauses US Varipulse Procedures Amid Safety Review, Investigates Brain-Related Events
Johnson & Johnson pauses U.S. Varipulse cases to investigate neurovascular events. The FDA-approved device integrates PFA therapy and 3D mapping for AFib treatment. 
Via Benzinga
J&J Falls — While Boston Scientific, Medtronic Pop — After Strokes Sideline A Key Product
The company paused sales of a key product, a rival to Boston Scientific and Medtronic, due to safety concerns. 
Via Investor's Business Daily
8 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Where to Invest $100,000 in 2025
Via The Motley Fool
< Previous 1 2
...
13 14 15 16 17 18 19 20 21
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.